| Day 1, Thursday, May 23rd | |
|---|---|
| 08:30-10:00 | BCMA-targeted therapies in myeloma: the new treatment frontier Pre-COMy CME Symposium |
| 10:00-10:20 | Coffee Break |
| 10:20-10:30 | COMy 2023 kick-off: Welcome by the Congress Co-Chairs |
| 10:30-12:00 | Session 1: Defining risk in myeloma |
| 12:00-12:30 | Lunch Break |
| 12:30-14:00 | Industry-supported Lunch Symposium Supported by Janssen |
| 14:00-14:10 | Technical Break |
| 14:10-15:35 | Session 2: Novel approaches for disease and response assessment |
| 15:35-15:45 | Technical Break |
| 15:45-17:15 | Industry-supported Lunch Symposium Supported by Adaptive Biotechnologies |
| 17:15-17:30 | Coffee Break |
| 17:30-18:30 | Session 3: Precursor conditions and other plasma cell disorders |
| 18:30-19:15 | Session 4: Plenary lectures |
| Day 2, Friday, May 24th | |
|---|---|
| 07:00-07:30 | Good Morning Breakfast |
| 07:30-08:15 | Breakfast Session |
| 08:15-08:25 | Technical Break |
| 08:25-09:25 | Session 5: IMS Session |
| 09:25-09:35 | Technical Break |
| 09:35-11:05 | Industry-supported Lunch Symposium Supported by BMS |
| 11:05-11:20 | Coffee Break |
| 11:20-12:30 | Session 6: Frontline management of newly diagnosed myeloma |
| 12:30-13:00 | Lunch Break |
| 13:00-14:30 | Industry-supported Lunch Symposium Supported by Janssen |
| 14:30-14:45 | Technical Break |
| 14:45-15:45 | Session 7: Practical management of specific situations |
| 15:45-16:00 | Coffee Break |
| 16:00-17:30 | Industry-supported Lunch Symposium Supported by Sanofi |
| 17:30-17:45 | Technical Break |
| 17:45-18:45 | Session 8: Plenary lectures |
| 18:45-19:45 | Award Ceremony Session: Presented by the Congress Co-Chairs |
| Day 3, Saturday, May 25th | |
|---|---|
| 07:00-07:15 | Good Morning Breakfast |
| 07:15-08:00 | Breakfast Session |
| 08:00-08:10 | Technical Break |
| 08:10-09:10 | Session 9: Novel agents under development |
| 09:10-09:20 | Technical Break |
| 09:20-10:50 | Is there a place for BCMA-based combinations in early RRMM? Industry-supported Lunch Symposium Supported by GSK |
| 10:50-11:10 | Coffee Break |
| 11:10-12:25 | Session 10: How I treat a relapsed/refractory myeloma |
| 12:30-13:00 | Lunch Break |
| 13:00-14:00 | An innovative therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM) Industry-supported Lunch Symposium Supported by Pfizer |
| 14:00-14:10 | Technical Break |
| 14:10-14:55 | Management of triple-class refractory patients in the absence of immunotherapies |
| 14:55-16:10 | Session 11: The road to cure: future protocols and directions |
| 16:10-16:30 | Coffee Break |
| 16:30-17:30 | CME Symposium |
| 17:30-17:40 | Technical Break |
| 17:40-18:10 | Session 12: Plenary lecture |
| 18:10-18:20 | In-Person Conclusions: Summary by the Congress Co-Chairs |
| Day 4 (ONLINE ONLY), Sunday, May 26th | |
|---|---|
| 10:15-11:30 | Multiple Myeloma communications I |
| 11:30-12:30 | Transforming Progress into Action in Relapsed/Refractory Multiple Myeloma CME Virtual Symposium |
| 12:30-13:45 | Mulitple Myeloma communications II |
| 13:45-14:15 | Final Panel Discussion and Conclusion |